Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must have genotype 1 chronic hepatitis C (CHC) and laboratory evidence of HCV infection for at least 6 months before the Screening Visit
Subjects will be treatment naïve
Subjects must have documentation of the presence or absence of cirrhosis
You may not be if
History or other clinical evidence of significant or unstable cardiac disease
Evidence of hepatic decompensation
Diagnosed or suspected hepatocellular carcinoma
Any other cause of significant liver disease in addition to hepatitis C, which may include but is not limited to malignancy with hepatic involvement, hepatitis B, drug-or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis
History of organ transplant, with the exception of corneal transplants and skin grafts
Clareo Health | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
